vasopressin role;induce;vasoconstriction;0;18038019
clamp glucose metabolic clearance rate;increase;hypo-osmolality;0;14681716
53 patient total;treat;acth;2;16466880
fst exposure;increase;plasma acth;2;12652345
bu224 administration;increase;acth;2;12652345
study;inject;aav vector arginine-vasopressin;2;14664791
vasopressin;secrete;pituitary gland;0;23121213
vasopressin;increase;blood pressure;0;23121213
vasopressin;decrease;organ donor catecholamine need;0;23121213
oxytocin;release;circulation pituitary gland;0;21810945
vasopressin;release;circulation pituitary gland;0;21810945
g receptor 54 receptor ligand administration;increase;plasma oxytocin level;2;21810945
oxytocin;increase;memory number;0;24387003
hormone secretion morphology impact view;induce;vasopressin;2;12492427
hormone secretion morphology impact view;induce;oxytocin;2;12492427
melatonin;suppress;rat system vp release;0;20814074
arginine vasopressin;secrete;pituitary gland;0;12524471
arginine vasopressin;secrete;pituitary gland;0;12524471
melatonin;express;myometrium;0;25015556
light melatonin level acute inhibition;suppress;contraction;0;25015556
sevoflurane period odour misinterpretation;mediate;melatonin decrease level;2;20962652
oxytocin;increase;prostaglandin synthesis;0;24947860
oxytocin;increase;prostaglandin synthesis;0;24947860
pituitary adenoma 31 patient;treat;somatostatin analog;2;18633321
arc receptor mrna;correlate;plasma insulin;2;21616134
arc leptin receptor mrna;correlate;plasma leptin concentration;0;21616134
arc leptin receptor mrna;correlate;content;0;21616134
gal-ir;express;prolactinoma;2;11940053
(3)- two-channel ge;induce;vasopressin;2;15844698
ge;induce;vasopressin;2;15844698
haemorrhage;decrease;hypothalamic vasopressin;2;12832724
plasma vasopressin increase;inhibit;galanin rat;0;12832724
oxytocin increase;inhibit;galanin rat;0;12832724
plasma vasopressin increase;treat;rat;0;12832724
oxytocin increase;treat;rat;0;12832724
type 3a receptor;activate;serotonin;2;16077169
5-ht3ar;activate;serotonin;2;16077169
stress;cause;plasma cortisol level elevation;2;17289277
latter increase availability;stimulate;insulin production;2;11735653
hypoglycemia stimulus;stimulate;vasopressin;2;17426098
stimulation;induce;two prolactin surge;2;176151421173932932219831262454215044075150339175011056481368612065949441237440587188747739340674092097232414328929933352122549159213672418694501933400176099584262367845542754054485217928537178871399192312649739113104340081646748716467488164103991070055811011015110156203732136367673412124758
oestradiol;induce;pregnancy restraint oxytocin neurone responsiveness;2;10718931
progesterone;induce;pregnancy restraint oxytocin neurone responsiveness;2;10718931
mouse;decrease;fast blood glucose level increase insulin sensitivity;2;23665701
finding;mediate;leptin effect;2;12697710
haemorrhage;decrease;hypothalamic vasopressin;2;12832724
plasma vasopressin increase;inhibit;galanin rat;0;12832724
oxytocin increase;inhibit;galanin rat;0;12832724
plasma vasopressin increase;treat;rat;0;12832724
oxytocin increase;treat;rat;0;12832724
olanzapine;induce;prolactin elevation;2;16185814
cortisol;increase;5 min;0;16698221
cortisol concentration;increase;be;0;20626675
nmda increase dose incubation;decrease;vasopressin release;2;11012837
kainate increase dose incubation;decrease;vasopressin release;2;11012837
ampa increase dose incubation;decrease;vasopressin release;2;11012837
cortisol;increase;bp;0;17386356
blood csf xenin;correlate;leptin marker blood level;2;22546776
blood csf xenin;correlate;insulin marker blood level;2;22546776
study;mediate;norepinephrine release effect;2;12654704
arousal;inhibit;serotonin opioid;2;19686432
nucleus oxytocin vasopressin neuron;stimulate;brainstem input parturition;0;11113350
leukocytic ldh activity;increase;animal blood glucose increase;2;24258289
stress;induce;standing oestrus acth injection;2;15951142
rat corticosterone intracerebroventricularly infusion;increase;acth;2;15240363
increase energy store;decrease;coeruleus dopamine-beta-hydroxylase expression;2;15240363
hyponatremia;release;vasopressin;2;10795929
receptor oxytocin synthesis;increase;phase;0;25219142
kainate;increase;oxytocin release;2;11762705
quisqualate;increase;oxytocin release;2;11762705
1;increase;oxytocin release;2;11762705
quisqualate group i mglur agonist;increase;oxytocin release;2;11762705
3-hpg group i mglur agonist;increase;oxytocin release;2;11762705
leptin;secrete;cell;0;11971053
melatonin;inhibit;dehydrogenase mrna expression;0;146731861058083575680071122979811231993113061771160054211691640119331581193710712062316123905041251988942215504223909864118687001099183569951887197099699737724991881810203008105098026745194623853160989763020078282800232193822926312272146027371542301642215842723385331848566164984119578861750475163993783817968319592839657883707078262008827443080773117964299776208376062534310502435263243638471748941870572215274956806258436701117862639396275916695225126331310601975
comparison;increase;acth corticosterone level;2;14654444
pco therapy;decrease;fin leptin level;2;14680609
oxytocin;release;mcn dendrite;0;12436939
oxytocin;inhibit;release;0;12436939
urine cortisol;suppress;dose suppression test 95 %;0;2316643210720040181742871291567912930931145023621467118718322123034617955456786218487840669005978906150897687009793762103576961571765910857554
oxytocinergic system analysis;increase;receptor;0;17540347707160564894034034849120629061209360512098589124091521242941912436933124509471245739312514227126007001271417512732226127303701285968612865897146095401462506214697497147547891514299148410516990264025929375269898993774900290391322636681313590131907114158231448480831505083220328361683822817782671298107719791075679206007968346136586576305847577773758825190655229167498921313692306309292631933762894835709560276957839396191469671680103726071044073115179541155821111582108915700048159312221593541016033310157987791630387016109416161545721648165910571489106032851062873710755683108888741094284711006435111038801110697011106975112743411152093111559479116892801173854211790516119107961205291512062902
cocaine administration;correlate;amygdalum oxytocin level aggression level;2;124799667862819751618881928357505454816136914880361325586878851860643831270851511513355104453697698186861470515139299025112921588394130209940225044221930726183124717094031850481228293195266882744963246124628200583927368286202360878442623043
gh acth concentration;decrease;cat somatostatin analog octreotide administration;0;18801640
cortisol concentration;decrease;cat somatostatin analog octreotide administration;0;18801640
neuroendocrine origin;cause;acth-dependent c;2;23140512
animal;treat;melatonin;2;11074456
vasopressin analog;release;teleosteus neurohypophysis;0;21569795
oxytocin analog;release;teleosteus neurohypophysis;0;21569795
nonapeptide oxytocin level;increase;man arousal;0;15664019
nonapeptide oxytocin level;increase;man orgasm;0;15664019
nonapeptide oxytocin level;increase;woman arousal;0;15664019
nonapeptide oxytocin level;increase;woman orgasm;0;15664019
hypothalamic tuberoinfundibular dopaminergic;inhibit;prolactin;0;2046305410940733286942511739329352050935532202887254246249519770852088869850477181047787909141791040979141338934515900920092022279247269930624693845729724019102018191022198910510245153456801556432411826263118976834706010894170102616678059073081421575554316254185164326281785344018096658191715661950022619299456731779861193216141934399553911517260
tida;inhibit;prolactin;2;2046305410940733286942511739329352050935532202887254246249519770852088869850477181047787909141791040979141338934515900920092022279247269930624693845729724019102018191022198910510245153456801556432411826263118976834706010894170102616678059073081421575554316254185164326281785344018096658191715661950022619299456731779861193216141934399553911517260
hypothalamic tuberoinfundibular dopaminergic;inhibit;prl;0;2046305410940733286942511739329352050935532202887254246249519770852088869850477181047787909141791040979141338934515900920092022279247269930624693845729724019102018191022198910510245153456801556432411826263118976834706010894170102616678059073081421575554316254185164326281785344018096658191715661950022619299456731779861193216141934399553911517260
haemorrhage;decrease;hypothalamic vasopressin;2;12832724
plasma vasopressin increase;inhibit;galanin rat;0;12832724
oxytocin increase;inhibit;galanin rat;0;12832724
plasma vasopressin increase;treat;rat;0;12832724
oxytocin increase;treat;rat;0;12832724
2 +;induce;vasopressin;2;12971956
vasopressin;increase;left ventricular;0;18541142
vasopressin;increase;lv;0;18541142
treatment;increase;acth;2;21687973
somatostatin;increase;pip (2)- level;0;15784846
somatostatin;decrease;level;0;15784846
oxytocin release;stimulate;hcg;0;12466354
insulin;increase;secretion;0;16236542
glucose;increase;secretion;0;16236542
leptin;increase;muscle glucose uptake;2;16236542
leptin;increase;oxidation;0;16236542
leptin;suppress;glucose output;2;16236542
ovary site acth level;induce;cell hypersecretion;0;16772282
leptin;express;adenoma;0;11824504
inability;stimulate;vasopressin secretion;2;17694689
hyperprolactinemia;inhibit;hormone;0;18025806
oxytocin;release;gland;0;15089967
oxytocin;release;gland;0;15089967
melatonin;inhibit;substance ot secretion;0;15613740
osmotic stimulation stress blunt acth response;correlate;neuron inability;0;11573986
transport;increase;plasma cortisol;2;16632387
sodium reabsorptive mechanism;upregulate;vasopressin escape;2;11158210
vasopressin;release;taurine;0;14617676106990757479859111335231112521611256079115497211175421311755895120071471210706712436929124924271451532853541694463734702110625627770667088584445860936686386509136807951870510066923100761811008715310422739105161121441616138383143062122139357281046367530880761587110828380
oxytocin;release;taurine;0;14617676106990757479859111335231112521611256079115497211175421311755895120071471210706712436929124924271451532853541694463734702110625627770667088584445860936686386509136807951870510066923100761811008715310422739105161121441616138383143062122139357281046367530880761587110828380
opioid;inhibit;oxytocin neurone;2;11058452
osmotic stimulus;cause;cycle plasma oxytocin increase;2;12377265
vasopressin administration;induce;hydrop;0;12897553
kainate;increase;oxytocin release;2;11762705
quisqualate;increase;oxytocin release;2;11762705
1;increase;oxytocin release;2;11762705
quisqualate group i mglur agonist;increase;oxytocin release;2;11762705
3-hpg group i mglur agonist;increase;oxytocin release;2;11762705
hypothalamus action;suppress;glucose production;2;24937445
insulin;signal;energy surfeit;0;19953342
insulin;signal;deficiency;0;19953342
lp;induce;plasma acth increase;2;18166492
arginine vasopressin;mediate;behavior hormone effect;0;10838478
oxytocin;stimulate;ruminant prostaglandinf2alpha secretion;0;10985415
leptin;express;adenoma;0;11824504
diabetes insipidus;cause;vasopressin mutation;2;14660745
fndus;cause;vasopressin mutation;2;14660745
5 vasopressin cell 4;induce;activity pattern;0;16497815
oxytocin receptor;suppress;progesterone;0;17765941
oxytocin receptor;suppress;p4;0;17765941
leptin circulate concentration;increase;october;0;18401941
insulin concentration;increase;september;0;18401941
exogenous glucocorticoid administration;downregulate;vasopressin;2;10795903
vasopressin;induce;dysrhythmium;0;16629866
vasopressin;induce;symptom;0;16629866
cortisol;increase;bp;0;17386356
halothane administration;increase;serum glucose;2;17988436
state;cause;plasma vasopressin level;2;12167778
avp;mediate;acth response;2;11488255
ot;mediate;acth response;2;11488255
vitro;stimulate;acth release;2;11488255
vitro;inhibit;acth secretion;2;11488255
leptin;secrete;tissue;0;21253519
vasopressin concentration;increase;one;0;11990905
insulin curve area;decrease;group;0;16483179
fast insulin curve area;decrease;group;0;16483179
melatonin;suppress;rat system vp release;0;20814074
tumor cell tr4 force overexpression;increase;proopiomelanocortin transcription acth secretion proliferation;2;23653479
acid;induce;oxytocin;2;12722132
dopamine;activate;production;0;15909246
oxytocin;activate;neurotransmission;0;15909246
oxytocin;release;mcn dendrite;0;12436939
oxytocin;inhibit;release;0;12436939
decrease;mediate;rat oxytocin;2;18702726
in vivo experiment;inject;leptin;2;15473128
in vivo experiment;inject;leptin;2;15473128
in vivo experiment;inject;leptin;2;15473128
dopamine;suppress;release elevation;0;20553721
leptin;interact;nucleus modulate energy balance receptor;0;11572787
cabergoline;treat;prolactinoma;2;20702648
bupropion;inhibit;norepinephrine;2;19039677
antidepressant bupropion;inhibit;dopamine;2;22512539
carbachol bst treatment;increase;plasma vasopressin level;2;21466795
glucocorticoid dexamethasone administration release blockade;prevent;plasma cortisol elevation;2;12379511
buspirone;increase;insulin level;2;15802819
prx-00023 treatment;increase;administration blood prolactin level;2;17495280
m;increase;serotonin level;2;23669068
vasopressin;secrete;neurohypophysis;0;12418301
somatostatin;decrease;rat activity;0;19414189
noradrenaline;release;stimulus response;0;15661433
oxytocin;increase;separation;0;22260655
mouse;treat;thioglucose;2;16715367
drinking;increase;blood glucose level;2;19485973
compartment 1 glucose distribution space glucose mass;increase;cow;0;11814033
compartment 1 glucose residence time;increase;cow;0;11814033
compartment 1 glucose distribution space glucose mass;decrease;cow;0;11814033
compartment 1 glucose residence time;decrease;cow;0;11814033
pvh trh neuron;express;leptin receptor;2;14764630
vasopressin infusion;decrease;norepinephrine requirement;2;21892977
lactation end hypoprolactinemia;cause;adult life body weight;0;18490438
symptom;cause;prolactin;2;23928066
serotonin transporter;release;neuron;0;15955412
noradrenaline response;mediate;response;0;21146475
noradrenaline response;mediate;response;0;21146475
serotonin reuptake inhibitor;cause;antidiuretic hormone secretion syndrome;0;20711296
growth factor;increase;dopamine 2 receptor expression;2;22684586
ngf;increase;dopamine 2 receptor expression;2;22684586
administration;induce;state prolactin increase;2;12084414
prolactin level;increase;olanzapine treatment;0;12084414
leptin;cause;ghrh-mediated gh release;0;12844339
prolactin;upregulate;secretion;0;12437072
prolactin;upregulate;secretion;0;12437072
adenoma;treat;prolactinoma;2;18657198
insulin administration;decrease;activity;0;24582678
vasopressin analog;release;teleosteus neurohypophysis;0;21569795
oxytocin analog;release;teleosteus neurohypophysis;0;21569795
net inhibitor reboxetine administration;increase;dopamine efflux;2;21669025
3 administration;increase;dopamine efflux;2;21669025
psychostimulant amphetamine administration;increase;dopamine efflux;2;21669025
0.5 mg\ per kg administration;increase;dopamine efflux;2;21669025
cocaine administration;increase;dopamine efflux;2;21669025
10 mg\ per kg administration;increase;dopamine efflux;2;21669025
patient;treat;vasopressin;2;10710939
somatostatin;activate;current;0;10805669
rat;treat;acth;2;15222631
reuptake inhibitor;increase;serotonin concentration;2;12690637
ect;increase;serotonin concentration;2;12690637
mao;increase;serotonin concentration;2;12690637
ect bupropion mao inhibitor;increase;noradrenaline concentration;2;12690637
lithium;increase;serotonin concentration increase;2;12690637
addition;interact;insulin signaling regulator;2;22513101
neurohypophysis component;release;vasopressin oxytocin pituicyte;2;19686441
acth;suppress;childhood seizure type;0;17368435
oxytocin;release;magnocellular neurone;0;15254151
prolactinoma;inhibit;(3)- h;0;18426817
bupropion;inhibit;dopamine reuptake;2;20140131
v2 vasopressin receptor;activate;g;0;16115624
risperidone;induce;antipsychotic prolactin elevation;2;17355517
labor;induce;oxytocin;2;12078439
norepinephrine;release;descend pathway;0;18343461
microm thp;decrease;dopamine content;2;16026929
atomoxetine reuptake inhibitor;increase;dopamine concentration;2;15115947
melatonin administration;increase;animal survival time;0;16180084
tumor rat;increase;melatonin administration;2;16180084
exposure;stimulate;dopamine release;2;22101517
prolactin;inhibit;dopamine;2;25453900
prl;inhibit;dopamine;2;25453900
stress increase cortisol;correlate;mood response;0;20176450
pancreatic;secrete;insulin;2;23211512
cell;secrete;insulin;2;23211512
pancreatic;secrete;insulin;2;23211512
cell;secrete;insulin;2;23211512
pancreatic;secrete;insulin;2;23211512
cell;secrete;insulin;2;23211512
pancreatic;secrete;insulin;2;23211512
cell;secrete;insulin;2;23211512
treatment;decrease;insulin release;2;23211512
neurotransmitter serotonin;stimulate;vasopressin secretion;0;12716407
5-ht;stimulate;vasopressin secretion;2;12716407
neurotransmitter serotonin;stimulate;oxytocin secretion;0;12716407
5-ht;stimulate;oxytocin secretion;2;12716407
serotonin reuptake inhibitor;treat;human depression;0;15379001
compound;inhibit;rat pituitary corticotrope crf-stimulated acth release;2;15867951
neuron type;mediate;hormone leptin action;2;24589844
leptin;secrete;adipose tissue;0;11327106
leptin;stimulate;receptor;0;11327106
leptin;decrease;food intake;0;11327106
leptin;increase;energy expenditure;0;11327106
patient sleepiness;correlate;morning melatonin level;2;21234339
patient obesity;correlate;morning melatonin level;2;21234339
mean prolactin level;decrease;8 week;0;20416024
rat corticosterone intracerebroventricularly infusion;increase;acth;2;15240363
increase energy store;decrease;coeruleus dopamine-beta-hydroxylase expression;2;15240363
plasma vasopressin level;increase;period;0;17258819
result;increase;vasopressin half-life;2;17258819
vglut2;express;vasopressin neuron;2;16101749
129xe;inject;mouse rat gh-3 prolactinoma;2;11550253
129xe;inject;mouse rif-1 fibrosarcoma gh-3 prolactinoma;2;11550253
study;increase;serotonin level;2;20816814
study;increase;dopamine level;2;20816814
ssrus administration;increase;serotonin level;2;20816814
sertraline administration;increase;dopamine concentration;2;20816814
sertraline administration;increase;dopamine concentration;2;20816814
vasopressin type 2 receptor antagonist;increase;heart failure case water clearance;0;15675332
dopamine transporter blockade;increase;dopamine concentration;0;18480679
amphetamine;increase;dopamine release;2;24191257
methylphenidate;inhibit;dopamine reuptake;2;24191257
methylphenidate;inhibit;norepinephrine reuptake;2;24191257
atomoxetine;increase;norepinephrine;2;16427661
i.p.;increase;norepinephrine;2;16427661
atomoxetine;increase;norepinephrine;2;16427661
i.p.;increase;norepinephrine;2;16427661
atomoxetine;increase;norepinephrine;2;16427661
i.p.;increase;norepinephrine;2;16427661
atomoxetine;increase;norepinephrine;2;16427661
i.p.;increase;norepinephrine;2;16427661
atomoxetine;increase;norepinephrine;2;16427661
i.p.;increase;norepinephrine;2;16427661
cytotoxic somatostatin analog an-238;express;receptor level;0;14508826
somatostatin receptor concentration tumor;suppress;cytotoxic somatostatin an-238;0;14508826
prolactinoma;treat;cabergoline agonist;0;19523354
prolactinoma;treat;bromocriptine agonist;0;19523354
adrenaline noradrenaline treatment;increase;level;0;20146024
dopaminergic agonist;induce;behavior;0;21655992
result;release;acth;2;22432126
endotoxemia;release;acth amount;2;22432126
cart;express;rat gastrin cell endocrine cell cell somatostatin cell;2;14729868
hypothalamus protein kinase phosphorylation;decrease;leptin coinjection;2;24735891
hypothalamus ampk phosphorylation;decrease;leptin coinjection;2;24735891
leptin coinjection;increase;cart\ per trh;0;24735891
food intake;induce;leptin coinjection;2;24735891
csf fistula;cause;skull base prolactinoma;2;23315667
osmotic stimulus;cause;cycle plasma oxytocin increase;2;12377265
cation transporter 3;express;dopaminergic neuron terminal;2;19416912
oct3;express;dopaminergic neuron terminal;2;19416912
alcohol treatment;increase;plasma acth cort level;2;22384198
ne transporter 2 action;mediate;brain norepinephrine part;2;11131159
vasopressin;increase;crh1 receptor mrna level;0;11337090
tyramine;activate;net norepinephrine transport;2;23450822
dopamine;encode;reward;0;25257296
melatonin;inhibit;substance ot secretion;0;15613740
somatostatin;inhibit;stimulate secretion;0;11290377
venlafaxine;inhibit;serotonin reuptake;2;12892015
antidepressant;inhibit;serotonin reuptake;2;12892015
serotonin-reuptake inhibitor;cause;dysfunction;0;12243609
irritable bowel syndrome;treat;serotonin reuptake inhibitor;2;16128675
sertraline exception ssri;increase;hyperprolactinemia risk;2;11249499
adrenaline;inhibit;insulin release;0;12172702
agonist;inhibit;insulin release;2;12172702
oxytocin receptor;increase;parturition model labor onset;0;15494465
cocaine mu opioid agonist;increase;dopamine concentration;2;12669175
disulfiram;inhibit;dopamine beta-hydroxylase;2;10723850
disulfiram;decrease;norepinephrine synthesis;2;10723850
patient;treat;octreotide somatostatin analog;2;19060447
acth;stimulate;development;0;11093622
acth;stimulate;hd mare milk electrolyte change;0;11093622
melatonin;secrete;bloodstream;0;24846082
melatonin;inhibit;ser307 phosphorylation;0;24846082
melatonin;increase;glut-4 expression;0;24846082
somatostatin;inhibit;growth factor secretion;0;24163059
prolactin;increase;anesthesia induction;0;11710990
escitalopram;cause;plasma cortisol increase;2;19662384
citalopram;cause;plasma cortisol increase;2;19662384
escitalopram;cause;prolactin increase;2;19662384
citalopram;cause;prolactin increase;2;19662384
leptin;stimulate;melatonin;2;18248398
pg synthesis inhibition;block;oxytocin effect;2;18039781
condition;cause;acth production;2;22993957
pituitary corticotrope adrenocorticotropic hormone;increase;inflammation;0;12624539
pituitary corticotrope acth;increase;inflammation;0;12624539
pituitary corticotrope adrenocorticotropic hormone;induce;lipopolysaccharide;0;12624539
pituitary corticotrope acth;induce;lipopolysaccharide;0;12624539
pituitary corticotrope adrenocorticotropic hormone;induce;lp;0;12624539
pituitary corticotrope acth;induce;lp;0;12624539
endogenous prolactin;inhibit;receptor isoform expression;0;22094470
antidepressant;block;noradrenaline;2;22419332
tca;block;noradrenaline;2;22419332
olanzapine;cause;glucose intolerance;2;23326434
prolactin level;increase;suckling;0;17174283
cocaine receptor agonist coadministration;prevent;dialysate dopamine alteration;2;11125013
cocaine kappa-agonist coadministration;prevent;dialysate dopamine alteration;2;11125013
dopaminergic agonist;induce;behavior;0;21655992
adrenaline noradrenaline treatment;increase;level;0;20146024
somatostatin analog treatment;induce;effect;0;18780796
dopamine agonist treatment;induce;effect;0;18780796
leptin;increase;lh secretion;0;11264725
gal-ir;express;prolactinoma;2;11940053
cell;treat;melatonin;2;24992189
change;mediate;plasma cortisol surge;2;17138651
defense exposure;increase;plasma oxytocin;2;11264675
patient sleepiness;correlate;morning melatonin level;2;21234339
patient obesity;correlate;morning melatonin level;2;21234339
breath co (2)-;increase;plasma cortisol level;2;16962720
clonidine;increase;dopamine output;2;18977208
0.003 mg\ per kg;increase;dopamine output;2;18977208
i.p.;increase;dopamine output;2;18977208
disease;cause;adrenocorticotropic hormone;2;25346922
disease;cause;acth;2;25346922
fluoxetine activity;mediate;serotoninergic receptor pathway effect;2;21098897
prolactin;inhibit;dopamine;2;25453900
prl;inhibit;dopamine;2;25453900
oxytocin;express;skin;0;22583056
vglut2;express;vasopressin neuron;2;16101749
study;inject;aav vector arginine-vasopressin;2;14664791
syndrome;cause;system serotonin;2;22010456
mrna;encode;aanat;2;17971073
dopamine agonist;treat;prolactinoma;0;19506475
oxytocin release;stimulate;hcg;0;12466354
dopaminergic agonist;induce;behavior;0;21655992
serotonin reuptake inhibitor;treat;group;0;14586482
gh;suppress;glucose tolerance test;2;17033266
mirtazapine;stimulate;norepinephrine release;2;12588077
mirtazapine;stimulate;serotonin release;2;12588077
buspirone;block;d2 dopamine presynaptic;2;19024168
5-hydroxytryptaminelum autoreceptor agonist;block;d2 dopamine presynaptic;2;19024168
result;mediate;leptin hormone effect;2;18479830
result;mediate;insulin hormone effect;2;18479830
subcutaneous;induce;hyperprolactinemia;2;19744546
7 week estrogen administration;induce;hyperprolactinemia;2;19744546
control group prolactin level;decrease;production period;0;12225766
cart;inhibit;glucose stimulate insulin secretion;2;16842887
tumor cell tr4 force overexpression;increase;proopiomelanocortin transcription acth secretion proliferation;2;23653479
aggrecan type ii collagen amount;decrease;degenerative group;0;25433723
rye product;induce;insulin response;2;21961929
melatonin;increase;crop production;0;22016420
infuse substantium nigra cytochrome c content increase;decrease;infusion level;0;12757852
infuse substantium nigra cytochrome c increase;prevent;treatment;0;12757852
cortisol;downregulate;mammal;0;21887296106605511043867710802282110079011172891812052464124642401254129612746316129145321295997114500557145190988268474197146954501343651832803762521890240716721108531991808207400417784128432789822477880674517942157155279711548622615618479156184841570995915947887159470671637638416457828167630831690199017535883175358841763446217641289174703711768999618096659182399791825868218931045190739031944808321451143178485598984741952533310674279
cortisol;downregulate;level;0;21887296106605511043867710802282110079011172891812052464124642401254129612746316129145321295997114500557145190988268474197146954501343651832803762521890240716721108531991808207400417784128432789822477880674517942157155279711548622615618479156184841570995915947887159470671637638416457828167630831690199017535883175358841763446217641289174703711768999618096659182399791825868218931045190739031944808321451143178485598984741952533310674279
somatostatin;bind;2;0;25297671
somatostatin;bind;5;0;25297671
dopamine;inhibit;activity;0;19020776
dopamine;prevent;mechanism;0;19020776
leptin;secrete;adipocyte;0;17184148
splenocyte;treat;melatonin concentration culture;2;25352055
interleukin-6 concentration;increase;significance melatonin application;2;25350595
interleukin-6 concentration;increase;361.32 235.22 pg\/ml 262.58 233.92 pg\/ml melatonin application;2;25350595
receptor expression;correlate;melatonin level;2;25369902
splenocyte;treat;melatonin concentration culture;2;25352055
interleukin-6 concentration;increase;significance melatonin application;2;25350595
interleukin-6 concentration;increase;361.32 235.22 pg\/ml 262.58 233.92 pg\/ml melatonin application;2;25350595
zdf rat;induce;tavn session melatonin secretion;2;253471851239590721951153639069582007167824545898889910381796159158512240874522731961228140231989536923059435225218552304676823269281232414312380914224968966108311541139449218289511197050331959568120065145193518021963272520605968212631162069204214990755
melatonin;release;gland;0;25346835
proanthocyanidin;mediate;collagen cross-linking;2;25379878
pac;mediate;collagen cross-linking;2;25379878
proanthocyanidin;enhance;dentin collagen base tissue property;2;25379878
pac;enhance;dentin collagen base tissue property;2;25379878
pac;decrease;collagen digestion;2;25379878
tropoelastin expression;increase;fibroblast;0;25319362
tropoelastin expression;treat;t. matsutake mycelium extract;0;25319362
collagen induce arthritis;induce;type ii collagen immunization;0;25375820
klotho expression;decrease;glucose tolerance;2;25377875
ormocomp;bind;apte maptm treat surface collagen iv;2;25375206
ape;decrease;collagen i elevation;2;25373883
2.6 5.2;decrease;collagen i elevation;2;25373883
ape;decrease;collagen iii expression elevation;2;25373883
2.6 5.2;decrease;collagen iii expression elevation;2;25373883
rvp;induce;fibrosis collagen 1a2 expression;2;25373595
rvp;induce;fibrosis collagen 1a2 expression;2;25373595
development elastin synthesis;cause;adulthood stiffness increase;0;25263973
28 day rat mc fruit extract administration;decrease;fast blood glucose level;2;25371774
28 day rat 1.5 body weight administration;decrease;fast blood glucose level;2;25371774
treatment;promote;procollagen type i production;2;25227288
increase elastin;stimulate;caha;0;25226004
receptor;binding;collagen;2;25369402
procedure;increase;collagen synthesis;2;25367711
result;induce;collagen fiber increase kinase muscle variation;2;25366571
atorvastatin;increase;cytochrome c reaction intensity;2;25366571
alcohol stressor variety;induce;collagen production;2;25142777
etoh stressor variety;induce;collagen production;2;25142777
100 etoh myocyte incubation;decrease;elastin;2;25142777
100 etoh myocyte incubation;decrease;increase collagen content;2;25142777
ampk inhibitor compound c;block;collagen stimulation;2;25142777
rgs5 deficiency;decrease;collagen content;2;25363362
collagen;increase;three model alveolar airway wall;0;25106431
bmp-12;release;collagen sponge;2;25354567
type i collagen expression;increase;concentration manner;0;25352963
elastin increase;trigger;cell necrosis;0;25010722117563191854464214578253147092041516177135463798862676189872721908825119074987196336551982002419837929198379271991093720508200203928662035976719577936208415042126633121267541216331772202505421185370219949602243766922745246231393622332812623349486237075151563210216046292160462951604631516218490161182501656751216841861168487001679913116968813176811491756988517884455185188221852283111874940
elastin increase;trigger;reaction;0;25010722117563191854464214578253147092041516177135463798862676189872721908825119074987196336551982002419837929198379271991093720508200203928662035976719577936208415042126633121267541216331772202505421185370219949602243766922745246231393622332812623349486237075151563210216046292160462951604631516218490161182501656751216841861168487001679913116968813176811491756988517884455185188221852283111874940
mbf;bind;pcm laminin collagen iv;2;25351253
visfatin;induce;collagen type iii production;2;25351242
collagen secretion;decrease;a549 culture medium ls-102 synoviolin inhibitor addition;0;25351210
hyperhomocysteinemia;increase;balloon injury rat vascular adventitium collagen type i accumulation;2;25350112
hhcy;increase;balloon injury rat vascular adventitium collagen type i accumulation;2;25350112
angiotensin ii;induce;collagen synthesis;2;25350112
ang ii;induce;collagen synthesis;2;25350112
hhcy;induce;collagen accumulation;2;25350112
dn cell;induce;glucose;2;25349198
dn mouse kidney;induce;glucose;2;25349198
dn cell;activate;collagen transcription;2;25349198
dn mouse kidney;activate;collagen transcription;2;25349198
salum;inhibit;elastin fragmentation;2;24916705
cell;treat;glucose;2;24904926
glucose;decrease;mmp-1 expression;0;24904926
hhcy;increase;elastin;2;24896329
hhcy;increase;collagen deposition;2;24896329
cse;increase;ecm molecule collagen i collagen iii fibronectin cell proliferation;2;25344066
cse;increase;ecm molecule collagen i collagen iii fibronectin deposition;2;25344066
fibrosis;prevent;collagen degradation effect;2;25343822
collagen cross-linking;decrease;kc progression;0;25343263
caffeine;inhibit;collagen biosynthesis;2;2534288512960921174888045432063432385471399612213589860379016709440174087001756747424275088178041111789931618491034183202911911499019427585195137552280947115164313
resistance training eight week;promote;heart failure rat collagen deposition improvement;2;2534054522595296222175592210017924427319110094381128342811412140114121411164114711849865120153431207020212957433150129251502053214707149428047213852519343838474123753551974848468922918910724216243107176070461798038718470531184034561805480919055995193249661956361619576194195615211994841520089973195245912081782820698833216945562123377221903877223549822243014723658728
hsya treatment;decrease;collagen synthesis amount;2;2533721817433563176788831767862917941891190840791918882819224893197006472056450721508343216772952219782523275087245481862512077211448960117392751200385512567893126447241282919216639718601637158945331608763516113066165568681714118318060181
pnpho covalent bond formation elastin incorporation;promote;stability;0;24731705
pnpho covalent bond formation elastin incorporation;promote;property;0;24731705
pnpho covalent bond formation elastin incorporation;promote;cell proliferation;0;24731705
domain 36;encode;elastin gene exon;2;24694619
work;release;tropoelastin proteolysis;2;24674658
work;release;tropoelastin proteolysis;2;24674658
synthesis;increase;elastin gene;2;24670922
collagen fluorescence intensity;increase;dadsc adsc group;0;2466416719072088200138482013137020568271206797262083075920528146213914252128756221858450219592382168906222359557225656362303153123197781233726962411502511304456118003741267141712903682146533581557778216425555165147971667682516826069171410881740974617895858182374941798998819089456
collagen increase;increase;session number;0;24641603
decrease elastin content increase;increase;session number;0;24641603
elastin content;decrease;age;0;2456157924637262
iium;cause;collagenolytic mmp-1 synthesis up-regulation;2;24525372
elastin secretion;decrease;6 month;0;24503000
fibrillin;interact;tropoelastin;2;24443019
peptide;encode;tropoelastin exon 28;2;24328291
lung fibroblast;increase;elastin type v collagen tenascin c. gene expression;2;24291458
mmp2 mt1-mmp cell surface content;induce;adiponectin;2;24255018
mmp2 activation cell surface content;induce;adiponectin;2;24255018
one hour collagenase treatment;cause;collagen fragmentation;0;24217223
one hour collagenase treatment;cause;collagen degradation;0;24217223
ear cartilage chondrocyte culture ltbp-2 addition;block;elastinogenesis;2;24148803
elastin-a;promote;cell differentiation;0;24141748
adv-ctgf;enhance;collagen iv expression;2;24052232
rofecoxib;inhibit;rat aorta elastin cross-linkage formation;2;24025789
know ascorbic acid;promote;elastin collagen production;2;24011462
inflammation;correlate;elastin amount;2;2390979423944903
effect;promote;collagen synthesis;2;23822553112267371083205212213097124802711248583012802724129145951502019215047682618872862239596327831106236682342041911225204388518626742242318416207637016454738127935897770591682459358139147946501490771314496670157069011577353716327169165431181757605017711532185839221908407919570628197232031989885720399614204266202070788922197825224665552186117011525868
o2 treatment;downregulate;type i collagen ecm molecule expression;2;23815460
o2 treatment;downregulate;elastin ecm molecule expression;2;23815460
lp exposure elastin deposition;prevent;exposure;0;23711546
formulation effect;prevent;uv irradiation elastin reduction;2;23702002
tropoelastin;trigger;mmp-12 expression;0;236712731108402021901569120821432339058210542079108077661095124110998135113108361213576614715913147663661503626315086768710789765479617890158861804587209858821030925014492660299846975991415615632106156535541596211716899711174985491822839117965753182430411848081218468477191443211955902520345904213620802110391321081222218850322179293711333270
tropoelastin;express;macrophage;0;236712731108402021901569120821432339058210542079108077661095124110998135113108361213576614715913147663661503626315086768710789765479617890158861804587209858821030925014492660299846975991415615632106156535541596211716899711174985491822839117965753182430411848081218468477191443211955902520345904213620802110391321081222218850322179293711333270
collagen;enhance;interaction;0;23625321
tropoelastin pre-incubation;increase;mmp-2 production;0;23597635
area change;correlate;elastic modulus tissue collagen content;2;23580144
melanin;increase;collagen;2;23579949
melanin;increase;elastin;2;23579949
plaque collagen;signal;cell behavior regulation;0;2356763910948197110401131170353912482545129392231295136114551157149665701813143774780076393268781485892101091184849151143957675396361931032377010428768105213691563930916051690162696611655685616801460176643741769788417531997184105951914478219168440192290592008980610666376108077421085947411106557
elastin content;decrease;increase elastase concentration treatment time;0;2355382715868802962825417343278177622891973370419900677206385232146655121874555111652841174467911871607120821433682546478829384506038138476965197337908220603097809748921831017428205940728313572315137107571560787710412460
artery chronic pulsation;cause;elastin collagen deposition;2;23509664163658651968071817846991197023431990968010917476109285171204444112631646151118411347891215947045168490242059847217762051
collagen elastin content;decrease;four decellularization condition time;0;23469868121774372322416089301021647395917098488171723031819305918065452189575152020189420210444197025131978064920733059206202462141772221548726939764
collagen image ic ratio;increase;two condition;0;23469868121774372322416089301021647395917098488171723031819305918065452189575152020189420210444197025131978064920733059206202462141772221548726939764
collagen image r;increase;two condition;0;23469868121774372322416089301021647395917098488171723031819305918065452189575152020189420210444197025131978064920733059206202462141772221548726939764
collagen image shg;increase;two condition;0;23469868121774372322416089301021647395917098488171723031819305918065452189575152020189420210444197025131978064920733059206202462141772221548726939764
collagen image skew;increase;two condition;0;23469868121774372322416089301021647395917098488171723031819305918065452189575152020189420210444197025131978064920733059206202462141772221548726939764
has-2 tropoelastin mmp-1 hgf expression;increase;gm-csf;0;2337269611075003159074421200289312184584124096761267141712843410145139601682606917069015172142681751867318357839184444841848081219041509190330791921303919374154200825712071509120516667209626432155724520926197223595391509123324647677683465751042389034511582556611391249
collagen waviness;decrease;degradation time;0;232970001516586912730082457696495769683330563227266331204364923628268278028090967465698051981579634016055757160065411588569916849214164884771725458917237244186471151865781319230148191598871932440719394942194843872008076620583273203547532065992821375736215991002105802521724865217300372223653221744269221892492230529015057970221710632262310910633258110365551145174912093072128375796075755
ambrisentan;prevent;reduce elastin expression;2;23292811198975638810589890456192792469675146970291010590017108731491097082211067800110996031129052911401896147365391010099310491078153475601577482416364719166506521621936116566828172933751757547117989387194028871955585618764741205252052062204220448055222876121978377519936184198549541993142620216169149903572039570021795061990959132347876825707509992812480877295127672512864642115288584
surface elastin;enhance;chondrocyte biocompatibility;0;23261552
artery;decrease;elastin content increase k s activity;2;23180031
a375 melanoma cell;treat;24 hour elastin concentration;2;23158148
elastin;induce;cell migration proliferation matrix synthesis cell activity range;0;23109320
elastin;induce;production cell activity range;0;23109320
pressure combination;promote;type iii collagen alp protein expression;2;23097075
twist stimulation combination;promote;type iii collagen alp protein expression;2;23097075
calpain-1 overexpression;induce;transform growth factor;0;2300673316436663162514261669087716918372170957331705667617151836173074381721185017452499179099451825885918288101184144361849329918519861194274931953872520040868207161282191175411118480114109321196724112480340125157561255187612743015128882541452224315081471151553841518091991012909194492942880516601233
mouse valve;correlate;collagen fraction increase;2;229845351747872817053986183908201959705219905878203750042086350421493863217760772186638510564146107644071077447811689801117146451193459712414444128757631294635612807887150620931525458441591726075755341451915549807754947861776498378231038793515546004155780861557341415796337162735351648868216450193166011941660791416740254169969351699576417845137
matrix metalloprotease;increase;glucose concentration increase;2;22966818
mmp;increase;glucose concentration increase;2;22966818
activity;increase;glucose concentration increase;2;22966818
corticosteroid posttreatment;decrease;collagen type;2;2296201016770071163443331700023517071719172933751817777817965320182640251872710518657064191102331924460418552709193012441950229119860666200223152009364620861353208212302093522820959141210547592068886721257142211101161082176710926289110996031110254711416869115879832189051122147379221642192216030622302193118466091211420812151307126295531266783112671110128392903982875826951879008318764225900606794284239731532976836310419836154479371581749916856047
collagen polypeptide;induce;uv radiation;0;22953877
syndrome lesion;cause;elastin gene haploinsufficiency;2;2289192017588872173954481762689618228265184048661844270318452001194682921993241419500474200899742004087019844261203607722019276120457133205908362047807820717154205390192096242919588272215078862188072321903938220490772223649122095981108439291094210411329012113954101196799912016585120821431241526212626514129255201451488912890646151329803171221206421518111661637804840580675056788575258874809392156709215671960776698193631020505715612329157215811571649916041365163316761642387416845061168934741720648817406209174064551740659317603475
treatment;increase;collagen type iii;2;22853187
mmc treatment;decrease;collagen elastin fiber amount;2;22828051
cmpc;express;collagen i;2;22820459
cmpc;express;elastin;2;22820459
angiotensin ii;enhance;collagen;2;228176061988122618495696220401462160607611121512105780021072528010988257115329011171150612364350123643541254445112560337128295221467825114718399150761591509723618594792192622271938061019451411197240241516600981872808978321104758881568783815547110156555301610325816043661162310031714598017572703181720551822748120649560
efficiency;decrease;increase collagen content;2;22750739
glucose;treat;elastin exhibit;0;24763624
glaucoma;cause;collagen decrease;2;22727818
glaucoma;cause;collagen decrease;2;22727818
glaucoma;cause;collagen decrease;2;22727818
estrogen;activate;collagen fiber synthesis;2;22727818
study;secrete;elastin;2;22718481
elastin fiber;prevent;ventricular chamber dilation;0;22718481
behavior difference;correlate;collagen ratio;2;22445610
fibrillin;interact;tropoelastin partner;2;2243895010636927165716471093046311238459171588811784603618228265188533621944653119584318195251022037500421175431213353212156114621683322108251731134790611470817128322861280788714523997146071191496267215062093150394391522332029834263447015316277026461533183122231712203073218522061852207172928416335701644824836457876917198120105778190675000037493032861736486139818617764865379490544369362480956619195669809817919100851381019829115837522164071781698481121546353
elastin degradation;mediate;metalloproteinase protease;0;22411928
diabetic rat;decrease;corpus cavernosum muscle\/collagen ratio;2;22403279
coq -lrb-10-rrb- treatment;promote;fibroblast increase type iv collagen expression proliferation;2;22339577
elastin synthesis;promote;level ec;0;22296557
iph;induce;elastin expression;2;222885971048300910207787168023641704575617295872176223211816174518240136185583561822198819393202196088671973044220107031206460002157417111129227112618201146569811966956123903271244078225962981898247177646685090488729037959375816325499
hmfc;increase;collagen type;2;22281808
hmfc;increase;collagen type;2;22281808
hmfc;increase;collagen type;2;22281808
hmfc;increase;collagen type;2;22281808
glycation;increase;collagen intensity;2;22277703
elastin;induce;knee chondrocyte glycosaminoglycan amount;0;22245318
elastin;induce;construct type ii collagen amount;0;22245318
insulin concentration;stimulate;proliferation;0;22236491
insulin effect;trigger;pi3k signaling pathway;0;22236491
insulin effect;activate;gene transcription;0;22236491
tropoelastin expression;increase;injury duration;0;222231972342400823424101
macrophage;increase;elastin;2;222231972342400823424101
radical;cause;collagen material alteration;2;22022154
collagen content;increase;zl zdf rat;0;2200823616901964170830711732474618195160204828732055067819696142206645442115101321771972216730481080360211040225113276401186325211897758123643541238445712414524124510131238831412574082126707501267585512679215126820821279909912782645147617801511791382282029453344159928191650520816636193
eplerenone;prevent;collagen content increase;2;2200823616901964170830711732474618195160204828732055067819696142206645442115101321771972216730481080360211040225113276401186325211897758123643541238445712414524124510131238831412574082126707501267585512679215126820821279909912782645147617801511791382282029453344159928191650520816636193
hydralazine;prevent;collagen content increase;2;2200823616901964170830711732474618195160204828732055067819696142206645442115101321771972216730481080360211040225113276401186325211897758123643541238445712414524124510131238831412574082126707501267585512679215126820821279909912782645147617801511791382282029453344159928191650520816636193
exosite 1 one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
2 one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
site one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
exosite 1 one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
2 one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
site one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
exosite 1 one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
2 one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
site one lesion combination;decrease;elastin competence;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
combination mutant asp124;enhance;elastin k;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
combination mutant asp124;enhance;elastin cat;2;219672331214478513130211511369315292230412483982274664500267233186661578625578221622176516480903166361881692873517096442227153420828532156718913157628226919783130977390547674964862678290654159302297963359498356149862271132601711554432115618400155339381578131216085114108716191101339611049739111665671151387411562940115759281706515517176253174985491770658717601747179974111780323718228265185003351833428818539597195843181985720119406173206558562066386612353914
collagen ii;express;sample;0;21908800
mmp-12 production;correlate;elastin degradation eosinophil count barrier permeability;2;21856305
collagen i transcription;increase;raise scar tissue;0;21838832
collagen i translation;increase;raise scar tissue;0;21838832
nir irradiation;increase;elastin;2;21833163118096480433841456883016875471194386882052390821408032215593198188885153815551554554016049894167067531691856116941737173005991745776418306155192713671966310719812595203454842136935912512648
antihypertensive therapy;decrease;collagen;2;21829037
age;decrease;matrix component collagen fiber synthesis;2;2182615310652273115572821171093611869737118865091223051212437452128095541438199147326401496553150362691768990518028961093209312217862125158651274217015175039153313991771153217957138190468301964151823425781548906086581963456347347030835219883534809362851070355327216901779861779049028125163820691982944688332640890147089348788962489899480890247019442117946248315623355167237011687735016987749172009429117985985682816405877176317831096213410974019111524691132008311399545192963041936196198842792030266203996142049064210468021123617242465424740282577359267422410085121100926501022215310506580
age;decrease;matrix component collagen fiber degradation;2;2182615310652273115572821171093611869737118865091223051212437452128095541438199147326401496553150362691768990518028961093209312217862125158651274217015175039153313991771153217957138190468301964151823425781548906086581963456347347030835219883534809362851070355327216901779861779049028125163820691982944688332640890147089348788962489899480890247019442117946248315623355167237011687735016987749172009429117985985682816405877176317831096213410974019111524691132008311399545192963041936196198842792030266203996142049064210468021123617242465424740282577359267422410085121100926501022215310506580
collagen iv labeling;decrease;media;0;21824826
collagen iv labeling;decrease;adventitium;0;21824826
fiber presence;promote;collagen increase;2;21800891
elastin;decrease;hhcy avf heart;0;2176096989289147890717942051995086510763084115009251189355212106681956224715992576160856801617212016195484162841821645080716464240171785941850424199135853354423543206378677647878023123499021273006214639017149755731563745315975610164610511651466521076854222297723641364810564100821971018833410524225105457741060644110694530111134581116973511179202112895021146175211863251119011821204516312076971121141841215410312388235145568521473275215047687151178451520517415217918156817081582183315851618810768983209678796111
akt pi3k activation inhibitor;block;type i collagen expression;2;2175121112681450146100661470234415056658565640291593742608030570719169425983793610446062155396341568182115807523157314941581483716227992168376501687082717209135172123591749393117607364176225101817203719779471
thiosulfate;inhibit;elastin calcification formation;2;217375161515355015168392513482388622630088221587021819369406165319811798965018818688190089091912979316191185
des;release;insoluble elastin;2;21726534113610201749478612730128126265141580262214109938183342881877249519144321107204091082516911278561127710091296369514563926151536681514286034355232022748809003479896087605614911176191650809218437930229793988469691094983561411487021
ide;release;insoluble elastin;2;21726534113610201749478612730128126265141580262214109938183342881877249519144321107204091082516911278561127710091296369514563926151536681514286034355232022748809003479896087605614911176191650809218437930229793988469691094983561411487021
cytokine factor;stimulate;collagen synthesis;2;21609573
elastin breakdown;prevent;mv-o;0;21562133762245516617093166988541698031017088559170717231729337517599828177041871793406218243041182039721827679619016471192701808560091146336291503407114693682152865461519191353346135530651696936470378516603478633383939941503608888860015386267098647937960776696145559710117100512781020717310486558105088261533332816300411161666221647024516913840198407641925194319854954108627841097082211099603941715811466403118154371243711212676771127070112745570199095916268051514649842770584766377913723791452021885630
elastin breakdown;prevent;induce lung injury;0;21562133762245516617093166988541698031017088559170717231729337517599828177041871793406218243041182039721827679619016471192701808560091146336291503407114693682152865461519191353346135530651696936470378516603478633383939941503608888860015386267098647937960776696145559710117100512781020717310486558105088261533332816300411161666221647024516913840198407641925194319854954108627841097082211099603941715811466403118154371243711212676771127070112745570199095916268051514649842770584766377913723791452021885630
tgf;increase;collagen production;2;213842001693068616877348174351081757978617887902105737751099242711176523113719521218710412757606126655341476734615117886152074642883922975140610192538104583911553505815467014154920091843036918279932186227031769092918406048196250421962505119831488161339161603887719569874163604821664349817293495
1;increase;collagen production;2;213842001693068616877348174351081757978617887902105737751099242711176523113719521218710412757606126655341476734615117886152074642883922975140610192538104583911553505815467014154920091843036918279932186227031769092918406048196250421962505119831488161339161603887719569874163604821664349817293495
iugr;decrease;birth elastin fiber formation transcript level;2;213639671297063012869365126828491463098415116139151728961517289735317622679260220654019909592002279767821882140898279570770075477974688929856908892391313189201877937439294588009585000964909310051278102107061551666416002560163968751638040716617452167239791672073216921131170653711714234917293375174288971822826518187616183888111821606318482625191444031951405920130146202272022009364620382748205252052086982010832740109708221109960311117232115364491164145511846609120723781212183712388463
iugr;decrease;day 7 elastin fiber formation transcript level;2;213639671297063012869365126828491463098415116139151728961517289735317622679260220654019909592002279767821882140898279570770075477974688929856908892391313189201877937439294588009585000964909310051278102107061551666416002560163968751638040716617452167239791672073216921131170653711714234917293375174288971822826518187616183888111821606318482625191444031951405920130146202272022009364620382748205252052086982010832740109708221109960311117232115364491164145511846609120723781212183712388463
ligb;bind;fibronectin type iii collagen;2;21347378162220031636204916988264173028001770734417606607179917491880965717296754173608421737186317629368177862331904355719079156190791781912975919028604193695281947398619581300193023251993086119997626205855791953846710890451112926401137157111568183119415711248598712890019146522021509411870740953682525205619114392389076937908298992490559333233979117010471461104857241051437215618142159964191611381716148523
study objective;increase;elastin synthesis;2;2128261810201117870263910404017104713179104703943841018849207188473641981321919962188197120461649108716674303165669111734512317584900180354121833883018412137179690241059023610870892120428651208214312684159129358181459775514704646153062281288208227136853199710205057
pup lung;increase;elastin deposition;2;21239531
liga leptospira immunoglobulin-like;bind;collagen;2;21219469
liga lig;bind;collagen;2;21219469
liga protein;bind;collagen;2;21219469
ligb leptospira immunoglobulin-like;bind;collagen;2;21219469
ligb lig;bind;collagen;2;21219469
ligb protein;bind;collagen;2;21219469
liga leptospira immunoglobulin-like;bind;elastin;2;21219469
liga lig;bind;elastin;2;21219469
liga protein;bind;elastin;2;21219469
ligb leptospira immunoglobulin-like;bind;elastin;2;21219469
ligb lig;bind;elastin;2;21219469
ligb protein;bind;elastin;2;21219469
tissue engineering scaffold elastin chain incorporation potential;induce;formation;0;21192640
hhcy;cause;vessel wall elastinolysis decrease elastic complicance;2;211261968828918891547989889259054838909965591948039264008935007294861299509248956224795870241625803116891444165146651681588616877562176226915792556802278980879817923362788250777680221058371410894806109979171101184211121376112546671150092511562419115924361171465211723030117334071200335312154090124298711250483512639825128187291517217415189131505791411913729479494276306319125381860333352802785871240758915038078416664847951882616818159199747422175862488582443859793989292619603539988407310225475104485231047589013960563140189261571784615886671161973011589538916085680
glucose level;increase;4v 3hb injection;0;21358145
reinforcement;mediate;forebrain increase dopamine level;2;25374094
cocaine;increase;area 1 mechanism rat dopaminergic neuron pacemaker burst firing frequency;2;25374094
increase muscle capillarization;increase;insulin sensitivity;2;25352432
muscle glucose uptake;enhance;muscle insulin improvement;0;25352432
muscle glucose uptake;signaling;glucose uptake;0;25352432
muscle glucose uptake;signaling;synthesis;0;25352432
adrenaline effect;block;nicergoline;0;25272708
adrenaline effect;block;10;0;25272708
adrenaline effect;block;-6;0;25272708
adrenaline effect;block;increase obzidan;0;25272708
adrenaline effect;block;10;0;25272708
adrenaline effect;block;-6;0;25272708
cockerel food intake ghrelin effect;mediate;2 receptor;0;25080314
insulin glucose injection;prevent;hypoglycemia;0;24684300
insulin glucose injection;prevent;thicken;0;24684300
bunazosin 1 receptor antagonist;induce;hypoglycemia presence insulin treatment;2;24684300
bunazosin 1 receptor antagonist;induce;adrenaline level presence insulin treatment;2;24684300
increase adrenaline;induce;hypoglycemia;0;24684300
increase adrenaline;promote;thicken;0;24684300
increase adrenaline;promote;muscle cell proliferation;0;24684300
leptin function;signal;energy balance state;0;25063755
leptin function;signal;decrease energy store state;0;25063755
roflumilast;suppress;collagen matrix protein stress;2;25035926
roflumilast;suppress;collagen matrix protein deposition;2;25035926
hormone adiponectin;promote;health;0;24998914
myocyte salvage;express;reduce scarring tissue collagen volume fraction;2;2392131424084223
adiponectin;increase;human cancer therapy;0;24998914
melatonin therapy;prevent;process;0;2486418820496471176531332095035921377060217782362256920821354772234089771694608118373554186392181851604518474830203713841992315819923380200256411912824010709970151000951548555415788706161836281693242722998574172555281737467920656021
melatonin treatment;prevent;effect;0;2486418820496471176531332095035921377060217782362256920821354772234089771694608118373554186392181851604518474830203713841992315819923380200256411912824010709970151000951548555415788706161836281693242722998574172555281737467920656021
melatonin;prevent;renin;0;2486418820496471176531332095035921377060217782362256920821354772234089771694608118373554186392181851604518474830203713841992315819923380200256411912824010709970151000951548555415788706161836281693242722998574172555281737467920656021
melatonin;prevent;receptor expression;0;2486418820496471176531332095035921377060217782362256920821354772234089771694608118373554186392181851604518474830203713841992315819923380200256411912824010709970151000951548555415788706161836281693242722998574172555281737467920656021
epinephrine tourniquet use;decrease;blood loss;0;21131843
epinephrine tumescence;decrease;blood loss;0;21131843
circulate ghrelin level;correlate;insulin level;2;22691550
adrenaline;upregulate;abcb1 gene expression;0;19380024
mrna expression;decrease;leptin;2;24703486
secretion;decrease;leptin;2;24703486
insulin;signaling;brain tissue protein;0;24651932
norepinephrine;increase;number mtt uptake;0;18441198151594031504403515494560714433125632862566608134663513500951452288129164881064227814630775870788480158813557932301394093079721723981513198224499856972103817561038426210452527105065541554883015711063158492361604028116266318163311111634437416394249164066801656544016566918167332281668250516908950103862521690217816679391170736131741645817459951175251611762028416139252106267541107869611518777118569131243714212563019126239981294398914656924147419091476981015311997
norepinephrine;increase;3h;0;18441198151594031504403515494560714433125632862566608134663513500951452288129164881064227814630775870788480158813557932301394093079721723981513198224499856972103817561038426210452527105065541554883015711063158492361604028116266318163311111634437416394249164066801656544016566918167332281668250516908950103862521690217816679391170736131741645817459951175251611762028416139252106267541107869611518777118569131243714212563019126239981294398914656924147419091476981015311997
norepinephrine;increase;rat aortic vsmc receptor incorporation;0;18441198151594031504403515494560714433125632862566608134663513500951452288129164881064227814630775870788480158813557932301394093079721723981513198224499856972103817561038426210452527105065541554883015711063158492361604028116266318163311111634437416394249164066801656544016566918167332281668250516908950103862521690217816679391170736131741645817459951175251611762028416139252106267541107869611518777118569131243714212563019126239981294398914656924147419091476981015311997
hpt axis effect;correlate;leptin level;2;24605825
clozapine;increase;blood glucose;2;17629416
clozapine;increase;insulin;2;17629416
myocyte death;induce;norepinephrine doxorubicin;2;17283256
insulin receptor stimulation;induce;rat adipocyte antilipolysis activation;0;17689141
rat cord preparation noradrenaline rhythm facilitation;mediate;receptor;0;16412573
alpha1-adrenergic receptor;mediate;norepinephrine;2;16225747
ar;mediate;norepinephrine;2;16225747
alpha1-adrenergic receptor;mediate;epinephrine;2;16225747
ar;mediate;epinephrine;2;16225747
acth response sensitisation;block;benoxathian;0;16219005
acth response sensitisation;block;benoxathian;0;16219005
noradrenaline;stimulate;ovulation;0;16026926
noradrenaline;promote;ovary development;0;16026926
obesity;promote;insulin resistance development;2;2437324311606777118183631186770512543260151410921516622630448822180312190846225202838429371791435020045141204135112053889620554934208711322119373521258337212823642141185921346062214020692171953422205519223029391090547215213227111934537248043535532378247133304351592456816000018160540991630637216702333168008461680193116914547172763531790922418317565182855531876568019120448191986471900922819414512195092791947070419956092198338902010371079842368001743756826474939651393336032781943281433328143422778500227922342271880922787141230520972323648523663741236637422388119023801581238138051123878315855324
diet;increase;insulin sensitivity;2;2437324311606777118183631186770512543260151410921516622630448822180312190846225202838429371791435020045141204135112053889620554934208711322119373521258337212823642141185921346062214020692171953422205519223029391090547215213227111934537248043535532378247133304351592456816000018160540991630637216702333168008461680193116914547172763531790922418317565182855531876568019120448191986471900922819414512195092791947070419956092198338902010371079842368001743756826474939651393336032781943281433328143422778500227922342271880922787141230520972323648523663741236637422388119023801581238138051123878315855324
adrenergic neurotransmitter;induce;adipocyte 2-deoxy-d-glucose uptake;2;15665039
beta1-adrenergic receptor;activate;glucose uptake;2;15665039
beta1-adrenergic receptor;stimulate;novel protein kinase c;0;15665039
norfenefrine;induce;glucose concentration decrease;2;15090628
norepinephrine;induce;glucose concentration decrease;0;15090628
urapidil tissue preperfusion;inhibit;glucose decrease;2;15090628
urapidil;enhance;concentration extracellular glucose level;2;15090628
flow;decrease;norepinephrine presence;2;15090628
orciprenaline;decrease;glucose concentration;2;15090628
d2 dopamine receptor;inject;rat nucleus;0;12970389
tropoelastin expression;increase;fibroblast;0;25319362
tropoelastin expression;treat;t. matsutake mycelium extract;0;25319362
p2y2r-mediated lox;release;induce collagen;2;25238333
bind tropoelastin activity;correlate;surface hydrophobicity;0;24856106
bind tropoelastin activity;correlate;carbon;0;24856106
bind tropoelastin activity;correlate;oxygen content;0;24856106
domain 36;encode;elastin gene exon;2;24694619
work;release;tropoelastin proteolysis;2;24674658
work;release;tropoelastin proteolysis;2;24674658
collagen increase;increase;session number;0;24641603
decrease elastin content increase;increase;session number;0;24641603
elastin content;decrease;age;0;2456157924637262
cmc;promote;type ii collagen proliferation;2;25394560
cmc;promote;type ii collagen secretion;2;25394560
loxl2;promote;collagen crosslink;2;25146937
loxl2;promote;elastin crosslink;2;25146937
iium;cause;collagenolytic mmp-1 synthesis up-regulation;2;24525372
strain;interact;collagen vi;2;244780751189543220979576146850921458583514871805152700943160661255784215732751574077822713778901588806598208522602119619521196249211493402148569421103913217224822157624621747391220537222231600222701652228053351254058511071275112926591181002316854559174985491821207618390756182000621844098218983664190844169065769903066519379663977772010419484104619491673461819502598195422242008157719765967201561962034590420644618
fibrillin;interact;tropoelastin;2;24443019
adenosine;stimulate;collagen;2;25393959
inosine;stimulate;collagen;2;25393959
adenosine;stimulate;collagen;2;25393959
inosine;stimulate;collagen;2;25393959
peptide;encode;tropoelastin exon 28;2;24328291
ear cartilage chondrocyte culture ltbp-2 addition;block;elastinogenesis;2;24148803
collagen mimetic peptide;mediate;protein self-assembly;0;25390880
fak ko wound;decrease;collagen density;2;25389925
i collagen protein;decrease;matrix decrease collagen;0;25387264
cmc;decrease;collagen deposition;2;25386220
ldr;upregulate;collagen type i alpha 1 expression;2;25384363
lkb1-deficient lung adc lysyl oxidase reduction;decrease;collagen disposition;2;2453112812577300129255201472956961318921881905192837084627428163675769897297314851049888415655419157699401616946416413471161872771624744416642001167150761673023716977322171865321728736317676035179344491759904818948947191118791940365619440335195615891966267719801978199311522012641020161759205591492066865820594926209563212103444121107086211244502112445121124456211024332110243421248838213166032143026921127502214719652223778122411819224643341067663411415930117516301253823822980975229607452362678324196716
lkb1-deficient lung adc lox reduction;decrease;collagen disposition;2;2453112812577300129255201472956961318921881905192837084627428163675769897297314851049888415655419157699401616946416413471161872771624744416642001167150761673023716977322171865321728736317676035179344491759904818948947191118791940365619440335195615891966267719801978199311522012641020161759205591492066865820594926209563212103444121107086211244502112445121124456211024332110243421248838213166032143026921127502214719652223778122411819224643341067663411415930117516301253823822980975229607452362678324196716
iium;cause;collagenolytic mmp-1 synthesis up-regulation;2;24525372
mmp-9 expression;treat;collagen deposition mucus secretion dexamethasone;2;25383084
timp-1 expression;treat;collagen deposition mucus secretion dexamethasone;2;25383084
mmp-9 expression;treat;collagen deposition mucus secretion hyssopus offcinali l.;2;25383084
timp-1 expression;treat;collagen deposition mucus secretion hyssopus offcinali l.;2;25383084
proanthocyanidin;mediate;collagen cross-linking;2;25379878
pac;mediate;collagen cross-linking;2;25379878
proanthocyanidin;enhance;dentin collagen base tissue property;2;25379878
pac;enhance;dentin collagen base tissue property;2;25379878
pac;decrease;collagen digestion;2;25379878
diabetes;cause;collagen molecule arrangement;2;24120383
collagen glycation;cause;collagen molecule arrangement;0;24120383
collagen glycation;cause;bone arrangement;0;24120383
collagen;binding;discoidin domain receptor-2;0;24120383
collagen;binding;ddr2;0;24120383
collagen;mediate;oxidase increase;0;24120383
conclusion;stimulate;collagen expression;2;24081158
conclusion;stimulate;collagen expression;2;24081158
lj-1888 pretreatment;inhibit;collagen i;2;24001475
collagen induce arthritis;induce;type ii collagen immunization;0;25375820105773012242147010936511115140261154937011821034120746901221816112509619129485473651866276474707844133404252338452824046675061927805766787131286338408871060896219089621919223572966641498363751045531410528210181634811952255619535279197512682007448220643120213719992197578821401925228708082287662110600330
ormocomp;bind;apte maptm treat surface collagen iv;2;25375206
ape;decrease;collagen i elevation;2;25373883
2.6 5.2;decrease;collagen i elevation;2;25373883
ape;decrease;collagen iii expression elevation;2;25373883
2.6 5.2;decrease;collagen iii expression elevation;2;25373883
rvp;induce;fibrosis collagen 1a2 expression;2;25373595
rvp;induce;fibrosis collagen 1a2 expression;2;25373595
28 day rat mc fruit extract administration;decrease;fast blood glucose level;2;25371774109041441093804811800069118293141215239312194501121964631262521712623881129020591518291730646537679418825593210368118155050891592793216861291173637431797952818241357195085702071691622045654221791502281954723444823237200142398337324470791
28 day rat 1.5 body weight administration;decrease;fast blood glucose level;2;25371774109041441093804811800069118293141215239312194501121964631262521712623881129020591518291730646537679418825593210368118155050891592793216861291173637431797952818241357195085702071691622045654221791502281954723444823237200142398337324470791
receptor;binding;collagen;2;2536940210681566241361661170587111598108121869491261188010352148162349851644031116912190172758381806862918245446183621841806576218373849191179851959003619387070194742922043243520509890205062382128909321461859213986982170177622223527227851172264087822695319232849372333550723761027237921742381092211004666
procedure;increase;collagen synthesis;2;25367711
result;induce;collagen fiber increase kinase muscle variation;2;25366571
atorvastatin;increase;cytochrome c reaction intensity;2;25366571
glycosylate lumican stimulation;increase;collagen type;2;23480731
glycosylate lumican stimulation;increase;collagen type;2;23480731
glycosylate lumican stimulation;increase;collagen type;2;23480731
1 mrna;increase;collagen type form level;2;23480731
study objective;promote;collagen cross-link development;2;234572192084701717631390218983402228458422673579227383402304178216674308941787694480609515057957144995887291771495718442706186652201142506811781013118530931245581812919876602121555476965128174940141816612184361230666301745630405163111052861612202713015508987634715868808990354399165392968278698310691325202413922926142133671638551816454361171952211762856821324931
rgs5 deficiency;decrease;collagen content;2;25363362
collagen crosslink;enhance;tumor cell persistence;0;233451611916522619111879193080671918753720103649198501472057088620556665208183762082289121324931212825642157027621919949106446691125453711642359118395551192061912119236124909591249249212492495124691221257730012707014127781351450355014503563153423763366935857911510393693156527461616946816258451163382261664200118282701185044371877755916707625168920351711032917087938173328791752524917211838180391101839040918814043
collagen crosslink;enhance;survival;0;233451611916522619111879193080671918753720103649198501472057088620556665208183762082289121324931212825642157027621919949106446691125453711642359118395551192061912119236124909591249249212492495124691221257730012707014127781351450355014503563153423763366935857911510393693156527461616946816258451163382261664200118282701185044371877755916707625168920351711032917087938173328791752524917211838180391101839040918814043
collagen crosslink;increase;tumor cell proliferation;0;233451611916522619111879193080671918753720103649198501472057088620556665208183762082289121324931212825642157027621919949106446691125453711642359118395551192061912119236124909591249249212492495124691221257730012707014127781351450355014503563153423763366935857911510393693156527461616946816258451163382261664200118282701185044371877755916707625168920351711032917087938173328791752524917211838180391101839040918814043
collagen crosslink;enhance;colonization;0;233451611916522619111879193080671918753720103649198501472057088620556665208183762082289121324931212825642157027621919949106446691125453711642359118395551192061912119236124909591249249212492495124691221257730012707014127781351450355014503563153423763366935857911510393693156527461616946816258451163382261664200118282701185044371877755916707625168920351711032917087938173328791752524917211838180391101839040918814043
collagen crosslink;enhance;growth;0;233451611916522619111879193080671918753720103649198501472057088620556665208183762082289121324931212825642157027621919949106446691125453711642359118395551192061912119236124909591249249212492495124691221257730012707014127781351450355014503563153423763366935857911510393693156527461616946816258451163382261664200118282701185044371877755916707625168920351711032917087938173328791752524917211838180391101839040918814043
matrix metalloprotease;increase;glucose concentration increase;2;22966818
mmp;increase;glucose concentration increase;2;22966818
activity;increase;glucose concentration increase;2;22966818
myocardium collagen deposition;correlate;capacity;0;22829703
myocardium collagen deposition;correlate;decrease degradation process;0;22829703
bmp-12;release;collagen sponge;2;25354567
lox;encode;cornea tissue variety collagen cross-linking;2;22661479109514652197994712766045147410015045349114314924064595323489784835135921651051168547213527761357535845823281002151669507786482185319278528916949327395338351579088415838508167686481686216116936089169385601757267317701901176454211856645918974171196543102003156820040588196669252150810112719068
type i collagen expression;increase;concentration manner;0;25352963
mbf;bind;pcm laminin collagen iv;2;25351253
mo;enhance;collagen accumulation;2;2234811961480381706813836093271348714149790095243592820711106828021117367211557576116411441248263612589052128653401451287514632214146359351465473414677857746984867030521378618015569352155200181573629915998679160204641609345616367803163914331727639917510091176902951769193018086952182975691837230619079548190992411881829719255345191763501954623619592613196174081988756520170634203717342073431120622177209349712087675921674707213498232138967410070142167356423992061
visfatin;induce;collagen type iii production;2;25351242
mo;enhance;collagen content;2;2234811961480381706813836093271348714149790095243592820711106828021117367211557576116411441248263612589052128653401451287514632214146359351465473414677857746984867030521378618015569352155200181573629915998679160204641609345616367803163914331727639917510091176902951769193018086952182975691837230619079548190992411881829719255345191763501954623619592613196174081988756520170634203717342073431120622177209349712087675921674707213498232138967410070142167356423992061
collagen secretion;decrease;a549 culture medium ls-102 synoviolin inhibitor addition;0;25351210
drug;block;lox loxl protein collagen cross-linking cd11b bmdc recruitment expression;2;2223174411152426116423591168988312615733126275231272686114507651150636851514495115488763441224787566168955077155925041584972716056258160966381634100716510593166420011723476417335808172446791700410617471532179143891818765318297062184384151853911219020076211613702118247821673063219113882186041019111879195498861980519219931152199463282002687420442288201519822081837620808300
hyperhomocysteinemia;increase;balloon injury rat vascular adventitium collagen type i accumulation;2;25350112
hhcy;increase;balloon injury rat vascular adventitium collagen type i accumulation;2;25350112
angiotensin ii;induce;collagen synthesis;2;25350112
ang ii;induce;collagen synthesis;2;25350112
hhcy;induce;collagen accumulation;2;25350112
dn cell;induce;glucose;2;25349198
dn mouse kidney;induce;glucose;2;25349198
dn cell;activate;collagen transcription;2;25349198
dn mouse kidney;activate;collagen transcription;2;25349198
glucose concentration;induce;reticulum;0;25405767
glucose concentration;induce;er;0;25405767
melatonin;cause;granulosa cell stress;0;25405739
stressed granulosa cell melatonin effect;inhibit;receptor antagonist luzindole;0;25405739
cmc;promote;type ii collagen proliferation;2;25394560
cmc;promote;type ii collagen secretion;2;25394560
glucose presence;inhibit;cell proliferation;0;25394466
fragment melatonin combination;induce;a;0;25393881
fragment melatonin combination;induce;oa;0;25393881
melatonin;prevent;age;0;25390004
insulin secretion;express;rardn;0;25389133
melatonin;decrease;mammary cell proliferation viability induce apoptosis;0;25384569
endotoxemia;increase;insulin secretion;2;2538378111266364170538321286902615220194152974388270128158643101628323717210129170907511742696017456850175194231830514118326786192400621977614019748889197208021971577220362554204241622120653321233852212823612135608421636801222761522255838122465073228205102257287722893028232504882303178923416061237472452362965924186868243471742481636712235117
klotho expression;decrease;glucose tolerance;2;25377875
rab2a knockdown;inhibit;insulin secretion;2;25377857
insulin receptor substrate 1;promote;bone formation;0;25372512
insulin receptor substrate 1;mediate;pi3k\/akt signaling;0;25372512
rgs5 deficiency;decrease;collagen content;2;25363362
e1 e2 adiponectin association;mediate;bmus;0;25405497
ft adiponectin association;mediate;bmus;0;25405497
obesity;decrease;adiponectin secretion;2;25400997
obesity;decrease;adiponectin secretion;2;25400997
addition;increase;insulin secretion;2;25388925
puberty begin leptin concentration;increase;year body percentage;0;25372383
puberty begin leptin concentration;increase;puberty risk;0;25372383
acth amount;decrease;uvb irradiation;0;25345490
mixed glucose\/protein beverage intake;decrease;boy level;0;25308907
rat group;treat;1 week insulin 5 iu;2;200419641554414715781983161499541652027716584985166749811695442317460301174825461782665917574405179623421808768818287387178799531841444818715471191117961901940119388364108404561110654811145010112415541537130942012021052602696869970337016483690373048833099632889739282800324827721386190841912112931287509483778159186043988875201893487190383709288759969965997749699817389102272941399951219659898112480481160092512518326125246881264592212947320146072131468959115325843
streptozotocin;decrease;insulin concentration;2;25065315
reference drug sitagliptin;increase;incretin insulin contents;2;25065315
control group;increase;glucose level;2;24771372
glucose level;decrease;day 16;0;24771372
insulin;stimulate;protein synthesis;0;25408462
hf mouse resv treatment;promote;glucose metabolism;2;25394648
insulin sensitivity vascular function hf symptom;enhance;diastolic function;0;25394648
insulin sensitivity vascular function hf symptom;enhance;vascular function;0;25394648
insulin sensitivity vascular function hf symptom;enhance;energy metabolism;0;25394648
sh-sy5y;treat;leptin;2;25403445
neuroblastoma cell line;treat;leptin;2;25403445
leptin;induce;expression;0;25403445
re rat treatment;decrease;leptin plasma level;2;25392295
hce75;increase;system serotonin dopamine level;2;25179173
400 mg\/kg;increase;system serotonin dopamine level;2;25179173
p.o.;increase;system serotonin dopamine level;2;25179173
excess glucose;induce;trimester trophoblast cell state;0;25394884
metformin;decrease;mouse blood glucose;2;25382002
glibenclamide;decrease;mouse blood glucose;2;25382002
insulin;upregulate;hl-7702 cell tfr1 protein mrna level;0;25385842
hormone melatonin;induce;piracetam bilobil;0;24400380
hormone melatonin;induce;open-field ginseng;0;24400380
rsv;prevent;rat induce insulin resistance;2;2535200811874812238721301512088315353412846443480079869032113104914081617972716227462163099611708619117112576172727861790855118250205182502141945517919641587205263832097472921241768216320752196533021950773223090332256473122209670218132712262716922587629229170162208130823185430231901272329209823462891236146932344849012939617
hormone melatonin;induce;piracetam bilobil;0;24400380
hormone melatonin;induce;open-field ginseng;0;24400380
28 day rat mc fruit extract administration;decrease;fast blood glucose level;2;25371774109041441093804811800069118293141215239312194501121964631262521712623881129020591518291730646537679418825593210368118155050891592793216861291173637431797952818241357195085702071691622045654221791502281954723444823237200142398337324470791
28 day rat 1.5 body weight administration;decrease;fast blood glucose level;2;25371774109041441093804811800069118293141215239312194501121964631262521712623881129020591518291730646537679418825593210368118155050891592793216861291173637431797952818241357195085702071691622045654221791502281954723444823237200142398337324470791
glucagon auc0-180 min;increase;dapa+meet;0;25370334
woman gestation 41 5\/7 week;induce;oxytocin;2;25415159
amylin;interact;time period leptin;2;25409701
amylin;interact;time period leptin;2;25409701
amylin;increase;leptin signaling;2;25409701
ns5a expression;enhance;glucose consumption;2;2439032119297321191016341985720419793818200625262013910321056986211469932148998821779165238247942259358622127214237758942330154223462180236299242383623412072493276635391578296495091341664313575683156993491610318716484368168920821696375717173481177847841809814618187620188206841885415418985028189769751915619519460998
bupropion;increase;noradrenaline;2;25427287
bupropion;increase;dopamine;2;25427287
bupropion;increase;noradrenaline;2;25427287
bupropion;increase;dopamine;2;25427287
bupropion;increase;noradrenaline;2;25427287
bupropion;increase;dopamine;2;25427287
bupropion;increase;noradrenaline;2;25427287
bupropion;increase;dopamine;2;25427287
serotonin depletion;block;cytisine effect;0;25288485
hyperprolactinemia patient;treat;agonist;0;25421155
hyperprolactinemia patient;treat;da;0;25421155
insulin secretion hyposmotic stimulation;inhibit;noradrenaline;2;17065814
leptin;suppress;feed;0;204171931927925117690262858493887170389575823979681113134413175746811834199519656487198238092041012317045623106150451080266610882542111604141139931611602618118402091197880412626355128015971453231714660021151749251536449247158114610605720865318285524181625157984236185680781894594519117547191877701321618813907995155279351558165915862893161005111625198616255002162846521643462416423896165957581660019016818872169824241698242517021366170213701740875917434149175964517813011
vasopressin;stimulate;collect duct sodium transport;0;11711512
vasopressin;release;hn;0;11427695
oxytocin;release;hn;0;11427695
vasopressin;release;pituitary gland;0;18344670
kainate;increase;oxytocin release;2;11762705
quisqualate;increase;oxytocin release;2;11762705
1;increase;oxytocin release;2;11762705
quisqualate group i mglur agonist;increase;oxytocin release;2;11762705
3-hpg group i mglur agonist;increase;oxytocin release;2;11762705
osmotic stimulus;cause;cycle plasma oxytocin increase;2;12377265
vasopressin concentration;increase;one;0;1199090511990939
vglut2;express;vasopressin neuron;2;16101749
laboratory task;induce;oxytocin change;2;1900508217289829168902301063222910941275124757311264629812746288707160566123383964793379385330412793204198279417922803211626832138568584083718300981815104574959288539307862988989161739071347907135691674989202224932675493647639483683950706596819581042042515319220143992721566401916554389165949808713975
vasopressin;mediate;v1 receptor activation vasoconstriction;0;157740809054839921818292679389386112942599995188669832689100678571022178510403611104477871051253310528604142015461056731110654495107289621111613411373409114293291143652211511958115555381166942511873030118936001195554211990905125945906336915682400561977153999236299729330005122950136326170229029882916660290716632534422764128254840827915892529763230295321979122169286224243918520131884613155818315721851303622161797113872931329579838743684985907686696837029283965248404107821414281314748160864806738575289967813742127326001279441612856123146055371463355514665508147075791476758414673520150909744299187434238048269271671491816307440213734677349918615633570284667345850713735871490506849407785991477156467498282864891386737529054835
shock patient 0.01 -0.04 u\ per min vasopressin infusion;increase;plasma vasopressin concentration;0;157740809054839921818292679389386112942599995188669832689100678571022178510403611104477871051253310528604142015461056731110654495107289621111613411373409114293291143652211511958115555381166942511873030118936001195554211990905125945906336915682400561977153999236299729330005122950136326170229029882916660290716632534422764128254840827915892529763230295321979122169286224243918520131884613155818315721851303622161797113872931329579838743684985907686696837029283965248404107821414281314748160864806738575289967813742127326001279441612856123146055371463355514665508147075791476758414673520150909744299187434238048269271671491816307440213734677349918615633570284667345850713735871490506849407785991477156467498282864891386737529054835
oxytocin;release;pituitary gland;0;21832819
vasopressin;inject;hippocampus;0;11033315
neurotensin;increase;nucleus oxytocin firing rate;2;15214863
vasopressin;stimulate;hepatocyte formation;0;22167837
turn;stimulate;acth release;2;19955761
haemorrhage;decrease;hypothalamic vasopressin;2;12832724
plasma vasopressin increase;inhibit;galanin rat;0;12832724
oxytocin increase;inhibit;galanin rat;0;12832724
plasma vasopressin increase;treat;rat;0;12832724
oxytocin increase;treat;rat;0;12832724
avp;mediate;acth response;2;11488255
ot;mediate;acth response;2;11488255
vitro;stimulate;acth release;2;11488255
vitro;inhibit;acth secretion;2;11488255
transport animal plasma acth;increase;1h;0;17029676
cortisol concentration;increase;transportation response;0;17029676
ntc animal crf injection;increase;plasma acth;2;17029676
ntc animal avp injection;increase;plasma acth;2;17029676
calmodulin;trigger;vasopressin;2;18290763
galanin fragment;prevent;plasma vasopressin level enhancement;2;15925363
vasopressin analog;release;teleosteus neurohypophysis;0;21569795
oxytocin analog;release;teleosteus neurohypophysis;0;21569795
melatonin;suppress;rat system vp release;0;20814074
vglut2;express;vasopressin neuron;2;16101749
picrotoxin;block;vasopressin oxytocin release increase;2;14552874
-;block;vasopressin oxytocin release increase;2;14552874
channel;block;vasopressin oxytocin release increase;2;14552874
blocker;block;vasopressin oxytocin release increase;2;14552874
otp null hypothalamus;secrete;neuropeptide somatostatin arginine vasopressin oxytocin hormone;2;11071765
osmotic stimulus;cause;cycle plasma oxytocin increase;2;12377265
neurohypophysis;secrete;oxytocin;2;11949004
hyperosmolality;inhibit;vasopressin neurone expression;2;15089976
vasopressin;release;taurine;0;14617676106990757479859111335231112521611256079115497211175421311755895120071471210706712436929124924271451532853541694463734702110625627770667088584445860936686386509136807951870510066923100761811008715310422739105161121441616138383143062122139357281046367530880761587110828380
oxytocin;release;taurine;0;14617676106990757479859111335231112521611256079115497211175421311755895120071471210706712436929124924271451532853541694463734702110625627770667088584445860936686386509136807951870510066923100761811008715310422739105161121441616138383143062122139357281046367530880761587110828380
neurohypophysis component;release;vasopressin oxytocin pituicyte;2;19686441
vgf protein expression;induce;insulin;2;22167530
nonacronymic protein expression;induce;insulin;2;22167530
vasopressin role;induce;vasoconstriction;0;18038019
oxytocin;release;mcn dendrite;0;12436939
oxytocin;inhibit;release;0;12436939
vasopressin two nonapeptide;secrete;neurohypophysis;0;10795914
oxytocin two nonapeptide;secrete;neurohypophysis;0;10795914
leptin;secrete;tissue;0;212535199294834934502794533379767543100236511010271010385613105230151056113710703894108648861097266311040226112085811171474511774095121181931275642812853417128857551289374015579059155830751585363615931394161834171659575817220191162452561635501216362081165183401661223516775598167939641680626017662916183707811846914218670590189712131920429919233863196867642045844535885648548812860860390007109087676912518692185039392493962129296609469733517982099498438979931162105671801079954210864587108689461171150111812752120704271224071012559213126943121279930614582047147157111517792115229341159571371609736316929141186825001877591918815209189827371909214619103999192041851954950720713919399364587721809035607911906191868919192234
leptin;inhibit;activity;0;18725075
adiponectin;activate;ampk;0;18725075
aahdd;induce;oxytocin 10 miu\ per ml;2;16819199
hypothalamic region cell pulse activity dynamics;treat;oxytocin;2;16047672
tumor addition;cause;acth;2;17572120
cortex hormone receptor expression;cause;acth;2;17572120
human hyperadrenocorticism criterion;prevent;hypercortisolemia;2;17572120
octreotide administration;prevent;hypercortisolemia;2;17572120
neurotensin;increase;nucleus oxytocin firing rate;2;15214863
5 vasopressin cell 4;induce;activity pattern;0;16497815
seventeen patient;treat;vasopressin;2;16047145
vasopressin addition;decrease;plasma 5-fu auc;0;16047145
origin;inhibit;acth secretagogue release;2;16395302
oxytocin;secrete;blood;0;12860046
arginine-vasopressin;secrete;blood;0;12860046
oxytocin labor induction;induce;afc;0;11880288
dopamine loss;cause;neuron ghrh reduce release;0;17003262
vasopressin infusion;decrease;requirement;0;21161222
plasma vasopressin level;increase;period;0;17258819
result;increase;vasopressin half-life;2;17258819
oxytocin;stimulate;uterus contraction;0;12609499
pituitary adenoma 31 patient;treat;somatostatin analog;2;18633321
group 1 acth day;correlate;il-1beta blood concentration;0;10844583
group 1 acth day;correlate;il-6 blood concentration;0;10844583
group 1 acth day;correlate;tnf-alpha blood concentration;0;10844583
glucocorticoid;suppress;oxytocin activation;2;15994343
vasopressin system;express;hormone globulin;0;15927785
oea;activate;oxytocin transmission;2;20554860107133851076625310805525112529921170055811790430121616021270068112955147129544303715453284281320875138126695785252375696659321512158790571615083616988703169021881712183817272659175120241742611518154499184510931843444418655871185528791884035819041747192472731941683319482229
pseudopregnancy day 2 adrenalectomy;increase;prolactin;2;12201221
gland growth;stimulate;growth hormone prolactin steroid estrogen progesterone;2;15876512
gland growth;stimulate;growth hormone prolactin steroid estrogen progesterone;2;15876512
gland growth;stimulate;growth hormone prolactin steroid estrogen progesterone;2;15876512
rat corticosterone intracerebroventricularly infusion;increase;acth;2;15240363
increase energy store;decrease;coeruleus dopamine-beta-hydroxylase expression;2;15240363
metformin insulin-sensitizing agent;decrease;appetite;0;2295006177373221709559396939341145759411602624120869351214515314742438150583051519508715375032162197201650523517717055182502731838276619819947195334811102456711735093118558501502872515680471158645309661644
pituitary hormone prolactin level;increase;response;0;21621331
neurohypophysis;secrete;oxytocin;2;11949004
cortisol;release;gland;0;12062310
dopamine;activate;production;0;15909246
oxytocin;activate;neurotransmission;0;15909246
decrease;mediate;rat oxytocin;2;18702726
behavior oxytocin effect;increase;ot;0;19703497
behavior oxytocin effect;increase;ot receptor expression;0;19703497
prolactin plasma concentration;increase;pregnancy concentration;0;20035106
vasopressin administration;suppress;latter activity;0;12866715
venlafaxine vasopressin memory administration;induce;vasopressin;0;12866715
vasopressin vasopressin memory administration;induce;vasopressin;0;12866715
tnf-alpha;increase;dopamine dopac concentration;2;12207161
abp;express;oxytocinergic neuron;2;14625054
mdma party drug;activate;brain oxytocin system;2;1847525483866118401595826680991972709397423954478898324419924739992474615539865155823831727891517050057167945641722768417287729171375611728927317035935173831051727265917420046176351371762957917672853176816561791507617925443179480301795632411274341115002471159144211739594117559021175513811802171118238971195991211992114162493391615083616339042163444601632778316378085164201631642912216401654167143251689023017143086168848651700001516904652172790631235951212496956155829161558926715588753153679241553649315808793158177481582108915898465159245551593122216046364160512051610253115798779161738691618783116112115165104731651047616574712165747141651336516594980166777101667772616741207168237201684345917921249179625521780452318056552177660591744312817888410179745881803717118092152175815361808617118302974107535841104353311070182125289901264628112700695127008821295443014534252146600421462799915044536150511431508179215111019150294721538037615512853564770518414384
gamma-hydroxybutyrate party drug;activate;brain oxytocin system;2;1847525483866118401595826680991972709397423954478898324419924739992474615539865155823831727891517050057167945641722768417287729171375611728927317035935173831051727265917420046176351371762957917672853176816561791507617925443179480301795632411274341115002471159144211739594117559021175513811802171118238971195991211992114162493391615083616339042163444601632778316378085164201631642912216401654167143251689023017143086168848651700001516904652172790631235951212496956155829161558926715588753153679241553649315808793158177481582108915898465159245551593122216046364160512051610253115798779161738691618783116112115165104731651047616574712165747141651336516594980166777101667772616741207168237201684345917921249179625521780452318056552177660591744312817888410179745881803717118092152175815361808617118302974107535841104353311070182125289901264628112700695127008821295443014534252146600421462799915044536150511431508179215111019150294721538037615512853564770518414384
ghb party drug;activate;brain oxytocin system;2;1847525483866118401595826680991972709397423954478898324419924739992474615539865155823831727891517050057167945641722768417287729171375611728927317035935173831051727265917420046176351371762957917672853176816561791507617925443179480301795632411274341115002471159144211739594117559021175513811802171118238971195991211992114162493391615083616339042163444601632778316378085164201631642912216401654167143251689023017143086168848651700001516904652172790631235951212496956155829161558926715588753153679241553649315808793158177481582108915898465159245551593122216046364160512051610253115798779161738691618783116112115165104731651047616574712165747141651336516594980166777101667772616741207168237201684345917921249179625521780452318056552177660591744312817888410179745881803717118092152175815361808617118302974107535841104353311070182125289901264628112700695127008821295443014534252146600421462799915044536150511431508179215111019150294721538037615512853564770518414384
oxytocin;interact;dopamine system;2;1847525483866118401595826680991972709397423954478898324419924739992474615539865155823831727891517050057167945641722768417287729171375611728927317035935173831051727265917420046176351371762957917672853176816561791507617925443179480301795632411274341115002471159144211739594117559021175513811802171118238971195991211992114162493391615083616339042163444601632778316378085164201631642912216401654167143251689023017143086168848651700001516904652172790631235951212496956155829161558926715588753153679241553649315808793158177481582108915898465159245551593122216046364160512051610253115798779161738691618783116112115165104731651047616574712165747141651336516594980166777101667772616741207168237201684345917921249179625521780452318056552177660591744312817888410179745881803717118092152175815361808617118302974107535841104353311070182125289901264628112700695127008821295443014534252146600421462799915044536150511431508179215111019150294721538037615512853564770518414384
change;increase;insulin secretion;2;11224661
change;increase;cortisol secretion;2;11224661
change;increase;epinephrine secretion;2;11224661
change;increase;norepinephrine secretion;2;11224661
vasopressin analog;release;teleosteus neurohypophysis;0;21569795
oxytocin analog;release;teleosteus neurohypophysis;0;21569795
alcohol drinking;cause;hyperprolactinemia;2;12351938
mouse;decrease;prolactin level;2;20831944
acth;decrease;tnf release;0;10890565
animal;inject;acth;2;19199814106383001731275911121291117659791261462712714017153642012089212575134156643151581136315891021160558411605584216055844160558451605584710696570
urine cortisol;suppress;dose suppression test 95 %;0;2316643210720040181742871291567912930931145023621467118718322123034617955456786218487840669005978906150897687009793762103576961571765910857554
labor woman seven percent;treat;oxytocin;2;2503103517904990184896971850758118607817173643061933057219461419181910071987804920121499205596732109959221158492225421172289595021764400230785162379425523583208161914601648881015955617163055731584007215802403132072461501598912850607119501791782643117575657173953491746758817289684236846971733681817181680169294141681421718715415
vasopressin v1a receptor mrna;increase;labor onset;0;11843375
oxytocin;induce;aqp2-containing cytoplasmic vesicle v2r-mediated redistribution;0;12411748
neuroendocrine cell;release;vasopressin;2;12744842
neuroendocrine cell;release;oxytocin;2;12744842
rat corticosterone intracerebroventricularly infusion;increase;acth;2;15240363
increase energy store;decrease;coeruleus dopamine-beta-hydroxylase expression;2;15240363
er;treat;prolactinoma;2;21422801
ovary site acth level;induce;cell hypersecretion;0;16772282
galp mrna;induce;brain action leptin;2;11713207
desmopressin;stimulate;adrenocorticotropic hormone secretion;2;227358602314408223155116
desmopressin;stimulate;adrenocorticotropic hormone secretion;2;227358602314408223155116
opioid;inhibit;oxytocin neurone;2;11058452
prolactin;inhibit;cell death;0;10959408
prolactin;inhibit;ecm remodel;0;10959408
receptor alpha-latrotoxin interaction;stimulate;vasopressin secretion;2;14604770
dopamine agonist;approve;purpose;0;12721511
somatostatin analog;approve;purpose;0;12721511
cortisol plasma level;increase;surgery;0;19615860
vasopressin plasma level;increase;surgery;0;19615860
norepinephrine plasma level;increase;surgery;0;19615860
dopamine plasma level;increase;surgery;0;19615860
cell line;express;insulin substrate 1;2;129173461135379411063744114085961141600211457825115838111168441111738029117424121160656411694516118097941178246928748363035302335926219702401528092138540384911868316835839499981966037929343796504674991948626671875214088930068901609911207392020371185061711809767121306739609109970332497225929737973983005798324281009261310187859103314191041879510574950106171471072275512151408124474431254059012609497485325911342042169216281824629667463681562864496352633992426429327930933555393954719575195104822401052143010751442108192371083614210842662110001141107571711147790111601341131390611343120
estrogen level;stimulate;plasma leptin concentration increase;2;10741011
insulin plasma concentration;increase;mouse;0;20298457
leptin plasma concentration;increase;mouse;0;20298457
t3\ per rt3-ratio;increase;insulin subject;2;21104580
vasopressin concentration;increase;one;0;1199090511990939
dietary treatment;induce;plasma insulin concentration difference;2;11882019
insulin;increase;cow proportion;0;11882019
acth cell treatment;increase;star cyp11a1 mrna expression;0;18609294
ewe acth secretion rate;increase;ewe comparison 1.5 factor;0;10698174
gonadectomy;increase;acth response;2;16879166
i;increase;acth response;2;16879166
olanzapine;induce;prolactin elevation;2;16185814
hypoglycemia stimulus;stimulate;vasopressin;2;17426098
relaxin-3 administration;increase;plasma acth level;2;24578294
oxytocin;release;mcn dendrite;0;12436939
oxytocin;inhibit;release;0;12436939
oxytocin analog;inhibit;myometrium activity;0;1535025115350245
nucleus stimulation;cause;oxytocin excitation;2;2404217511906204128234691518691546169987299324612489771047136662071669696639986514007113401093238402363840237375574737950933436393233617614482047519964177205451988122020197643
nucleus stimulation;cause;oxytocin excitation;2;2404217511906204128234691518691546169987299324612489771047136662071669696639986514007113401093238402363840237375574737950933436393233617614482047519964177205451988122020197643
administration;increase;prolactin circulate level;2;10644541
vp-free igg autoab;correlate;plasma cortisol;2;20932870
vasopressin system;express;hormone globulin;0;15927785
hypogonadism;mediate;hyperprolactinemia;2;20080927
participant;correlate;age bmus homa waist circumference morning cortisol;2;19277910
leptin;interact;hormone;0;16420334
oxytocin;increase;hydrolysis;0;12141571
treatment;increase;acth;2;21687973
oxytocin;stimulate;milk election uterine contraction;0;22506444
oxytocin;induce;mother behavior;0;22506444
vasopressin;release;taurine;0;14617676106990757479859111335231112521611256079115497211175421311755895120071471210706712436929124924271451532853541694463734702110625627770667088584445860936686386509136807951870510066923100761811008715310422739105161121441616138383143062122139357281046367530880761587110828380
oxytocin;release;taurine;0;14617676106990757479859111335231112521611256079115497211175421311755895120071471210706712436929124924271451532853541694463734702110625627770667088584445860936686386509136807951870510066923100761811008715310422739105161121441616138383143062122139357281046367530880761587110828380
stimulation;release;cortisol;2;24388184
npy;increase;acth;2;16675522
uptake;induce;coitus orgasm oxytocin;2;21210957
study;inject;oxytocin;2;21210957
stress;induce;standing oestrus acth injection;2;15951142
mc4r ligand;induce;oxytocin release;2;14614094
gene;encode;prolactin;2;20798550
gene;encode;oxytocin;2;20798550
hyperprolactinemia;cause;dysfunction;0;23232756
dopamine action;mediate;five receptor subtype;0;12486173
plasma vasopressin level;increase;period;0;17258819
result;increase;vasopressin half-life;2;17258819
immobilization stress;induce;water intake sham-operated psc group plasma acth increase;2;14765982
serotonergic activation;induce;leptin;2;12873793
sonic hedgehog;express;dopaminergic projection course choice point;2;19774071118045711238378012509125126790311297189415234346152941438091209777401676195289119220926248215737744157469141603380016571630170862031933960019447091
shh;express;dopaminergic projection course choice point;2;19774071118045711238378012509125126790311297189415234346152941438091209777401676195289119220926248215737744157469141603380016571630170862031933960019447091
oxytocin;increase;hydrolysis;0;12141571
mc4r ligand;induce;oxytocin release;2;14614094
oxytocin;induce;depolarization;0;18171940
oxytocin;induce;neuron current;0;18171940
oxytocin;stimulate;milk ejection;0;22902166
oxytocin;stimulate;contraction;0;22902166
dopamine effect;mediate;receptor;0;11504182
dopamine effect;mediate;receptor subtype;0;11504182
vasopressin;activate;urea transport;0;16641165
vasopressin;block;opc-31260;0;16641165
